Ohtuvayre denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for ohtuvayre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Ohtuvayre on Medical-Necessity Grounds

Ohtuvayre (ensifentrine) is an inhaled dual inhibitor of phosphodiesterase 3 and 4 approved by the FDA as a maintenance treatment for COPD. Aetna's medical-necessity denials for this drug typically rest on insufficient documentation that the patient's COPD severity, symptom burden, and prior treatment history justify adding a newer agent. Insurers routinely apply internal clinical criteria — derived from the FDA label, applicable GOLD guideline recommendations, and their own coverage policy — and deny when the submitted chart does not explicitly map to each requirement.

## Why This Denial Is Appealable

A medical-necessity denial is a coverage determination, not a final word. Federal law gives you the right to challenge it at multiple levels:

• Internal appeal (ERISA §503 / ACA §2719): Your plan must provide a full-and-fair review. Submit within the deadline stated in your denial letter (commonly 180 days for ERISA plans).
• External review (ACA §2719): After exhausting internal appeals — or after 4 months from the denial — you may request an Independent Review Organization (IRO) review. The IRO's decision is binding on the plan.
• Expedited review: If a standard timeline would seriously jeopardize your health, request expedited external review; a decision is typically required within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation: Spirometry reports and clinical notes confirming your COPD diagnosis and current severity classification per your treating physician. 2. Symptom burden: Chart entries documenting persistent symptoms (breathlessness, exacerbation frequency, activity limitation) despite current therapy. 3. Prior-treatment history: A dated, outcomes-annotated list of every inhaler class and combination you have tried — including why each was discontinued or deemed inadequate. 4. Prescriber medical-necessity letter: A letter from your pulmonologist or prescribing physician explaining, in clinical terms, why Ohtuvayre is medically necessary for you specifically and why existing alternatives are insufficient. 5. Relevant guideline support: A reference to the applicable GOLD COPD guideline recommendation for your disease category (ask your physician to cite the guideline organization, not specific numbers).

## Criteria-Mapping Structure

Obtain Aetna's published Clinical Policy Bulletin for Ohtuvayre (available on aetna.com under "Clinical Policy Bulletins"). Print each listed criterion. For every requirement, write the exact chart fact that satisfies it — date, source document, and physician name. Submit this side-by-side table with your appeal letter. Reviewers are required to weigh documented evidence; an explicit criterion-by-criterion response forces engagement with your records rather than a form denial.

## Next Step

Call the Member Services number on your Aetna card, confirm the internal appeal address, and ask for the specific Clinical Policy Bulletin number governing Ohtuvayre. Request the complete administrative record underlying your denial, including any medical review notes. You have the right to that record under ERISA.